Eli Lilly planning expansion of research centre in India: CEO David Ricks
New York: Eli Lilly is planning the expansion of its research centre in India and will be partnering with other Indian companies. Eli Lilly CEO David Ricks highlighted this after a roundtable interaction with PM Narendra Modi in New York.
“We have already a large research-based centre in India. We plan to grow that. More importantly, the products we make, particularly for common conditions like obesity, diabetes which inflict so many Indians – we will be bringing to this market at scale, partnering with other Indian companies, with producers in India and helping people with healthier life in India…It is an exciting moment to work with India” Eli Lilly CEO added.
He also highlighted that India is emerging as an economic superpower.
As per ANI report, Ricks noted that during the interaction with PM Modi on Sunday, he shared ideas about technological advancements and AI.
“We had a wonderful meeting with PM Modi to exchange ideas about the advancement of technology, use of AI and biotechnology and the growth of India as an emerging superpower economically” said Ricks.
Eli Lilly and Company operates in India through two distinct business entities, expanding its pharmaceutical and drug development capabilities across the region.
The company’s operations extend beyond India, covering neighboring countries such as Nepal, Bangladesh, and Sri Lanka through distribution and promotion partnerships with local pharmaceutical companies.
In addition, Eli Lilly established ‘Eli Lilly Services India Pvt. Ltd’ in January 2016 by opening a capability centre in Bangalore.
Medical Dialogues team had earlier reported that the U.S. Food and Drug Administration (USFDA) had approved Eli Lilly's eczema drug for use in adults and children above 12 years old.
The drug, which is an injectable medicine and branded Ebglyss, will be available in the next few weeks, the company had said.
Read also: Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production
